Literature DB >> 30666433

Bloodstream infections with vancomycin-resistant enterococci are associated with a decreased survival in patients with hematological diseases.

Sarah Weber1,2, Michael Hogardt3,4,5, Claudia Reinheimer3,4,5, Thomas A Wichelhaus3,4,5, Volkhard A J Kempf3,4,5, Johanna Kessel3,6, Sebastian Wolf7,3, Hubert Serve7,3, Björn Steffen7,3, Sebastian Scheich7,3.   

Abstract

Enterococcus species are commensals of the human gastrointestinal tract with the ability to cause invasive infections. For patients with hematological diseases, enterococcal bloodstream infections (BSI) constitute a serious clinical complication which may even be aggravated if the pathogen is vancomycin-resistant. Therefore, we analyzed the course of BSI due to vancomycin-susceptible enterococci (VSE) in comparison to vancomycin-resistant enterococci (VRE) on patient survival. In this retrospective single-center study, BSI were caused by VRE in 47 patients and by VSE in 43 patients. Baseline patient characteristics were similar in both groups. Concerning infection-related characteristics, an increased CRP value and an increased rate of prior colonization with multidrug-resistant organisms were detected in the VRE BSI group. More enterococcal invasive infections were found in the VSE group. The primary endpoint, overall survival (OS) at 30 days after BSI, was significantly lower in patients with VRE BSI compared to patients with VSE BSI (74.5% vs. 90.7%, p = 0.039). In a multivariate regression analysis, VRE BSI and a Charlson comorbidity index higher than 4 were independent factors associated with 30-day mortality. Moreover, we found that VRE with an additional teicoplanin resistance showed a trend towards an even lower OS.

Entities:  

Keywords:  Bloodstream infections; Hematological diseases; Multidrug-resistant organisms; Survival; Vancomycin-resistant enterococci

Mesh:

Year:  2019        PMID: 30666433     DOI: 10.1007/s00277-019-03607-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  10 in total

1.  The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections.

Authors:  Oryan Henig; Jason M Pogue; Emily Martin; Umar Hayat; Mahmoud Ja'ara; Paul E Kilgore; Raymond Cha; Sorab Dhar; Keith S Kaye
Journal:  Open Forum Infect Dis       Date:  2020-05-06       Impact factor: 3.835

2.  Does vancomycin resistance increase mortality in Enterococcus faecium bacteraemia after orthotopic liver transplantation? A retrospective study.

Authors:  S Dubler; M Lenz; S Zimmermann; D C Richter; K H Weiss; A Mehrabi; M Mieth; T Bruckner; M A Weigand; T Brenner; A Heininger
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-31       Impact factor: 4.887

3.  Risk Factors for the Acquisition of Enterococcus faecium Infection and Mortality in Patients with Enterococcal Bacteremia: A 5-Year Retrospective Analysis in a Tertiary Care University Hospital.

Authors:  Atsushi Uda; Katsumi Shigemura; Koichi Kitagawa; Kayo Osawa; Kenichiro Onuma; Yonmin Yan; Tatsuya Nishioka; Masato Fujisawa; Ikuko Yano; Takayuki Miyara
Journal:  Antibiotics (Basel)       Date:  2021-01-11

4.  Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis.

Authors:  Sarah Weber; Aaron Magh; Michael Hogardt; Volkhard A J Kempf; Maria J G T Vehreschild; Hubert Serve; Sebastian Scheich; Björn Steffen
Journal:  Ann Hematol       Date:  2021-05-03       Impact factor: 3.673

5.  Clinical and microbiological characteristics of bloodstream infections caused by Enterococcus spp. within internal medicine wards: a two-year single-centre experience.

Authors:  Tommaso Lupia; Gianmario Roberto; Luca Scaglione; Nour Shbaklo; Ilaria De Benedetto; Silvia Scabini; Simone Mornese Pinna; Antonio Curtoni; Rossana Cavallo; Francesco Giuseppe De Rosa; Silvia Corcione
Journal:  Intern Emerg Med       Date:  2022-01-29       Impact factor: 5.472

6.  Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I).

Authors:  German A Contreras; Jose M Munita; Shelby Simar; Courtney Luterbach; An Q Dinh; Kirsten Rydell; Pranoti V Sahasrabhojane; Rafael Rios; Lorena Diaz; Katherine Reyes; Marcus Zervos; Helina M Misikir; Gabriela Sanchez-Petitto; Catherine Liu; Yohei Doi; Lilian M Abbo; Luis Shimose; Harald Seifert; Carlota Gudiol; Fernanda Barberis; Claudia Pedroza; Samuel L Aitken; Samuel A Shelburne; David van Duin; Truc T Tran; Blake M Hanson; Cesar A Arias
Journal:  Open Forum Infect Dis       Date:  2021-12-23       Impact factor: 4.423

7.  Near-ubiquitous presence of a vancomycin-resistant Enterococcus faecium ST117/CT71/vanB -clone in the Rhine-Main metropolitan area of Germany.

Authors:  Ursel Heudorf; Trinad Chakraborty; Linda Falgenhauer; Moritz Fritzenwanker; Can Imirzalioglu; Katrin Steul; Marlene Scherer
Journal:  Antimicrob Resist Infect Control       Date:  2019-07-29       Impact factor: 4.887

8.  Analysis of Vancomycin-Resistant Enterococci in Hemato-Oncological Patients.

Authors:  Kristýna Hricová; Taťána Štosová; Pavla Kučová; Kateřina Fišerová; Jan Bardoň; Milan Kolář
Journal:  Antibiotics (Basel)       Date:  2020-11-07

9.  Clonal distribution of vancomycin-resistant Enterococcus faecium in Turkey and the new singleton ST733.

Authors:  Fatma Erdem; Cigdem Kayacan; Oral Oncul; Alper Karagoz; Zerrin Aktas
Journal:  J Clin Lab Anal       Date:  2020-10-06       Impact factor: 3.124

10.  Changing epidemiology of vancomycin-resistant Enterococcus faecium: Results of a genome-based study at a regional neurological acute hospital with intensive care and early rehabilitation treatment.

Authors:  Linda Falgenhauer; Ingeborg Preuser; Can Imirzalioglu; Jane Falgenhauer; Moritz Fritzenwanker; Dietrich Mack; Christoph Best; Ursel Heudorf; Trinad Chakraborty
Journal:  Infect Prev Pract       Date:  2021-03-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.